Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose
ConclusionsDTC patients treated with 131-radioiodine after rhTSH stimulation have lower abdominal radioiodine activity than hypothyroid patients. Our data could be of practical relevance in terms of patient management. The potential impact on rare radioiodine-related gastrointestinal side effects is to be established in specifically designed prospective studies.
Source: Endocrine - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Endocrinology | Gastric (Stomach) Cancer | Gastroenterology | Hypothyroidism | Liver | PET Scan | Radioiodine Therapy | Study | Thyroid | Thyroid Cancer | Urology & Nephrology